Annual Report And Financial Statements

Overview

The report describes the company's 2024 progress in commercialising its liquid biopsy platform, including new pharma contracts and revenue of £2.9 million. It presents a targeted ESG assessment focused on six UN SDGs and references GRI, the UN Global Compact, WHO and SASB. The company employed 119 staff at year end, 60% of whom were female, and continued initiatives on inclusion, health and safety, waste and sustainable practices. The report also highlights the Group's ongoing investment in clinical laboratories, assays and molecular workflows.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services